Shaperon (Biopharma, Biotechnology) — Funding, Investors & Signals 2026

Shaperon

Delivering the future of IMMUNOLOGY

Founded 2008

Korea South 23 employees Series C Total: $26.00B Biopharma, Biotechnology

Shaperon is a clinical stage biotech company with a focus on developing novel inflammasome inhibitors (small molecule). Their unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines, including IL-1β, IL-18, IL-6, and TNF-α, by controlling both priming and activation phase of inflammasome. This approach sets them apart from conventional methods that only target the activation phase. Currently, Shaperon is focused on developing multiple clinical programs in various health areas such as atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, and NASH, leveraging their novel modality. In addition to their inflammasome R&D programs, Shaperon is also involved in anti-viral and anti-cancer nanobody therapeutics. With proprietary immunized nanobody libraries and high throughput screening combined with in vitro/in vivo systems, they are accelerating the development of multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases. Founded in 2008 and headquartered in Korea South, Shaperon recently received a substantial KRW26.00B Series C investment at 20 October 2020 from a consortium of investors including Smilegate Investment, Posco Capital, JX Partners, Albatross Investment, Seoul Investment Partners, BNK Venture Capital, Nova M Healthcare, Moorim Capital, and Yuanta Investment. This infusion of capital reflects the confidence that these investors have in the potential of Shaperon's innovative approach to addressing immune-mediated inflammatory disorders and their advancements in nanobody therapeutics.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	••••••	9	•••• ••••	20 Oct 2020

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

••••••

•••• ••••

20 Oct 2020

FAQ About Shaperon

Delivering the future of IMMUNOLOGY

Shaperon was founded in 2008.

Shaperon is headquartered in Korea South.

Shaperon operates in the following industries: Biopharma, Biotechnology.

Shaperon has approximately 23 employees.

Shaperon has completed 1 funding round, raising a total of $26.00B. The latest funding stage is Series C.

Top alternatives and competitors to Shaperon include Cardiol Therapeutics Inc. , Renibus Therapeutics Inc, in2cure, Active Biotech AB, ImmuNext. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Shaperon and Cardiol Therapeutics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Shaperon

General Information

Track Shaperon

Discover More

About Shaperon

Funding Rounds & Investors (1)

Shaperon Alternatives & Competitors

FAQ About Shaperon

Don't just browse. Track.